Combination of cannabinoids and n-acylethanolamines

1. A pharmaceutical composition comprising a therapeutically-effective amount of at least one cannabinoid or a salt thereof, and at least one N-acylethanolamine or a salt thereof, wherein the at least one cannabinoid is tetrahydrocannabinol (THC), and wherein the at least one cannabinoid and the at least one N-acylethanolamine are present in the composition in a molar ratio of about 1:0.2 to about 1:2000.

2. The pharmaceutical composition of claim 1 , wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:0.2 to about 1:5.

3. The pharmaceutical composition of claim 1 , wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:0.5 to about 1:2.

4. The pharmaceutical composition of claim 1 , wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:15 to about 1:1800.

5. The pharmaceutical composition of claim 1 , wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:25 to about 1:450.

6. The pharmaceutical composition of claim 1 , wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:50 to about 1:100.

7. The pharmaceutical composition of claim 1 , comprising about 200-1800 mg of N-acylethanolamine or a salt thereof.

8. The pharmaceutical composition of claim 7 , comprising about 250 mg, about 500 mg, about 750 mg, about 1000 mg or about 1500 mg of N-acylethanolamine or a salt thereof.

9. The pharmaceutical composition of claim 1 , wherein the N-acylethanolamine is selected from the group consisting of N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), a salt thereof, or any combination thereof.

10. The pharmaceutical composition of claim 9 , wherein the N-acylethanolamine is PEA or a salt thereof.

11. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition comprises about 0.5-10 mg of THC or a salt thereof, and about 200-1800 mg of PEA or a salt thereof.

12. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition comprises about 2.5-10 mg of THC or a salt thereof, and about 250-1000 mg of PEA or a salt thereof.

13. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises about 2.5 mg, about 5 mg, about 7.5 mg or about 10 mg THC or a salt thereof, and about 250 mg, about 500 mg, about 750 mg or about 1000 mg PEA or a salt thereof.

14. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, sublingual, inhalational, topical, rectal, vaginal, parenteral, intravenous, intramuscular, or subcutaneous administration.

15. The pharmaceutical composition of claim 14 , wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, or sublingual administration.

16. The pharmaceutical composition of claim 1 , wherein the therapeutic potency of the pharmaceutical composition is increased compared to the same pharmaceutical composition without the N-acylethanolamine.

17. The pharmaceutical composition of claim 1 , wherein the required therapeutic dosage of the cannabinoid in the pharmaceutical composition is decreased compared to the same pharmaceutical composition without the N-acylethanolamine.

18. The pharmaceutical composition of claim 1 , wherein at least one of the side-effects of the cannabinoid is reduced compared to the same pharmaceutical composition without the N-acylethanolamine.

19. The pharmaceutical composition of claim 1 , wherein the therapeutic window of the cannabinoid is extended compared to the same pharmaceutical composition without the N-acylethanolamine.

20. A dosage unit comprising a therapeutically-effective amount of a pharmaceutical composition comprising at least one cannabinoid or a salt thereof, and at least one N-acylethanolamine or a salt thereof, wherein the at least one cannabinoid is tetrahydrocannabinol (THC), and wherein the at least one cannabinoid and the at least one N-acylethanolamine are present in the composition in a molar ratio of about 1:0.2 to about 1:2000.

21. A dosage unit consisting essentially of a therapeutically-effective amount of at least one cannabinoid or a salt thereof, and at least one N-acylethanolamine or a salt thereof, wherein the at least one cannabinoid is tetrahydrocannabinol (THC), and wherein the at least one cannabinoid and the at least one N-acylethanolamine are present in the composition in a molar ratio of about 1:0.2 to about 1:2000.

22. A method for preventing or treating at least one symptom of Tourette syndrome in a human subject in need thereof, comprising administering to the subject a therapeutically-effective amount of a pharmaceutical composition comprising at least one cannabinoid or a salt thereof, and at least one N-acylethanolamine or a salt thereof, wherein the at least one cannabinoid is tetrahydrocannabinol (THC), and wherein the at least one cannabinoid and the at least one N-acylethanolamine are present in the composition in a molar ratio of about 1:0.2 to about 1:2000, thereby preventing or treating the symptom.

23. The method of claim 22 wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:0.2 to about 1:5.

24. The method of claim 22 wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:0.5 to about 1:2.

25. The method of claim 22 wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:15 to about 1:1800.

26. The method of claim 22 wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:25 to about 1:450.

27. The method of claim 22 wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:50 to about 1:100.

28. The method of claim 22 , wherein the pharmaceutical composition comprises about 200-1800 mg of N-acylethanolamine or a salt thereof.

29. The method of claim 28 , wherein the pharmaceutical composition comprises about 250 mg, about 500 mg, about 750 mg, about 1000 mg or about 1500 mg of N-acylethanolamine or a salt thereof.

30. The method of claim 22 , wherein the at least one N-acylethanolamine is N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), a salt thereof, or any combination thereof.

31. The pharmaceutical composition of claim 30 , wherein the N-acylethanolamine is PEA or a salt thereof.

32. The method of claim 22 wherein the pharmaceutical composition comprises THC or a salt thereof, and PEA or a salt thereof.

33. The method of claim 22 wherein the pharmaceutical composition comprises about 0.5-10 mg of THC or a salt thereof, and about 200-1800 mg PEA or a salt thereof.

34. The method of claim 22 wherein the pharmaceutical composition comprises about 2.5-10 mg of THC or a salt thereof and about 250-1000 mg of PEA or a salt thereof.

35. The method of claim 22 wherein the pharmaceutical composition about 2.5 mg, about 5 mg, about 7.5 mg or about 10 mg of THC or a salt thereof, and about 250 mg, about 500 mg, about 750 mg or about 1000 mg of PEA or a salt thereof.

36. The method of claim 22 wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, sublingual, inhalational, topical, rectal, vaginal, parenteral, intravenous, intramuscular, or subcutaneous administration.

37. The method of claim 36 wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, or sublingual administration.

38. The method of claim 22 , wherein the administration of the cannabinoid and N-acylethanolamine is repeated.

39. The method of claim 38 , wherein the administration of the cannabinoid and the N-acylethanolamine is repeated until a beneficial change in the condition of the subject according to the Yale Global Tic Severity Scale (YGTSS) is achieved compared to the condition of the subject prior to treatment.

40. The method of claim 38 , wherein the administration of the cannabinoid and the N-acylethanolamine is repeated until a beneficial change in the condition of the subject according to at least one scale selected from the group consisting of (i) the Clinician Global Impression scale (CGIS), (ii) the Gilles de la Tourette Syndrome-Quality Of Life scale (GTS-QOL) (iii) the Tourette Syndrome Symptom List (TSSL) (iv) the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) (v) the ADHD Rating Scale-IV (ADHD-RS) and (vi) the Hamilton Anxiety Rating Scale (HAM-A), is achieved compared to the condition of the subject prior to treatment.

41. The method of claim 22 , wherein the Tourette syndrome is classified as moderate to severe Tourette syndrome.

42. The method of claim 22 , wherein the symptom is tics.

43. A method for preventing or treating emesis in a human subject in need thereof, comprising administering to the subject a therapeutically-effective amount of a pharmaceutical composition comprising at least one cannabinoid or a salt thereof, and at least one N-acylethanolamine or a salt thereof, wherein the at least one cannabinoid is tetrahydrocannabinol (THC), and wherein the at least one cannabinoid and the at least one N-acylethanolamine are present in the composition in a molar ratio of about 1:0.2 to about 1:2000, thereby preventing or treating the emesis.

44. The method of claim 43 wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:0.2 to about 1:5.

45. The method of claim 43 wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolarnine or a salt thereof is between about 1:0.5 to about 1:2.

46. The method of claim 43 wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:15 to about 1:1800.

47. The method of claim 43 wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:25 to about 1:450.

48. The method of claim 43 wherein the molar ratio between the at least one cannabinoid or a salt thereof, and the at least one N-acylethanolamine or a salt thereof is between about 1:50 to about 1:100.

49. The method of claim 43 , wherein the pharmaceutical composition comprises about 200-1800 mg of N-acylethanolamine or a salt thereof.

50. The method of claim 49 , wherein the pharmaceutical composition comprises about 250 mg, about 500 mg, about 750 mg, about 1000 mg or about 1500 mg of N-acylethanolamine or a salt thereof.

51. The method of claim 43 , wherein the at least one N-acylethanolamine is N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine ((DEA), palmitoylisopropylamide (PIA), a salt thereof, or any combination thereof.

52. The pharmaceutical composition of claim 51 , wherein the N-acylethanolamine is PEA or a salt thereof.

53. The method of claim 43 wherein the pharmaceutical composition comprises THC or a salt thereof, and PEA or a salt thereof.

54. The method of claim 43 wherein the pharmaceutical composition comprises about 0.5-10 mg of THC or a salt thereof, and about 200-1800 mg of PEA or a salt thereof.

55. The method of claim 43 wherein the pharmaceutical composition comprises about 2.5-10 mg of THC or a salt thereof and about 250-1000 mg of PEA or a salt thereof.

56. The method of claim 43 wherein the pharmaceutical composition comprises about 2.5 mg, about 5 mg, about 7.5 mg or about 10 mg of THC or a salt thereof, and about 250 mg, about 500 mg, about 750 mg or about 1000 mg of PEA or a salt thereof.

57. The method of claim 43 wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, sublingual, inhalational, topical, rectal, vaginal, parenteral, intravenous, intramuscular, or subcutaneous administration.

58. The method of claim 57 wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, or sublingual administration.

59. The method of claim 43 , wherein the administration of the cannabinoid and the N-acylethanolamine is repeated.